3x founder

Martin Bittner

Co-Founder & CEO, Redouble AI (YC S24)︱If Your Enterprise Runs on Java, so Should Your Agents︱JVM-Native Agentic AI Operating System for In-Stack Enterprise Workflow Automation

Co-founder

Redouble AI· Summer 2024 🇺🇸 New York, New York, United States

in LinkedIn

2025AI Fellow· Define Ventures

Founder · since 2018

Company

Define Ventures

Role

AI Fellow

Stage

—

no public source

Raised

—

no public source

Based

San Francisco, California, United States

Founder / co-founder — the company's markEmployee / research role

Source: LinkedIn work history

Profile coverage5 of 7 · missing posts, contact

Redouble AI

Java-native multi-agentic AI operating system for enterprise

Summer 2024

Experience

Career

Redouble AI
Co-founder
Co-Founder & CEO · New York, NY · 2024 – Present
2024
Forbes Technology Council
Member and Contributor · New York, NY · 2025 – Present
2025
University of Oxford
Guest Speaker for Course on GenAI, Cloud, and ML Ops · Oxford, England, United Kingdom · 2019 – Present
2019
Define Ventures
AI Fellow · San Francisco, California, United States · 2025
2025
Y Combinator
Co-founder
YC Summer 2024 · San Francisco, California, United States · 2024
2024
Arctoris
Co-founder
Co-Founder & CEO · Oxford, England, United Kingdom · 2018 – 2024
2018
Creative Destruction Lab
CDL-Oxford, AI, 2019/20 Cohort · Oxford, England, United Kingdom · 2019 – 2020
2019
Young Academy of the German National Academy of Sciences
Expedition Physician · Ecuador · 2020
2020
Fraunhofer Institute
Junior Group Leader · Stuttgart, Germany · 2017 – 2018
2017
University Medical Center Freiburg
Resident in the Department of Radiation Oncology · Freiburg, Germany · 2014 – 2017
2014

Bio

Martin Bittner is a serial entrepreneur in AI and automation for complex enterprise workflows. Before co-founding Redouble AI, he was the CEO of Arctoris, a successful pharma workflow automation company which he co-founded and led from inception to scale. In terms of background, Martin obtained his MD from the University of Freiburg in Germany, his DPhil in Oncology as a Rhodes scholar at the University of Oxford, and his MBA from The Wharton School.